ESCRS - O9 - EARLY POST-OPERATIVE ANTERIOR CHAMBER PARAMETERS MODIFICATIONS INDUCED BY PRESERFLO MICROSHUNT IN PRIMARY OPEN-ANGLE GLAUCOMA

EARLY POST-OPERATIVE ANTERIOR CHAMBER PARAMETERS MODIFICATIONS INDUCED BY PRESERFLO MICROSHUNT IN PRIMARY OPEN-ANGLE GLAUCOMA

Published 2023 - 27th ESCRS Winter Meeting

Reference: O9 | Type: Free Paper Submission | DOI: 10.82333/3mwq-mj30

Authors: Matteo Mario Carlà* 1 , Gloria Gambini 1 , Tomaso Caporossi 1 , Alfonso Savastano 1 , Federico Giannuzzi 1 , Stanislao Rizzo 1

1Ophthalmology Department, “Fondazione Policlinico Universitario A. Gemelli, IRCCS”,Rome,Italy

Purpose

The aim this study is to determine anterior chamber parameters variations induced by PreserFlo MicroShunt implantation, in the early post-operative days.

Setting

Prospective monocentric observational study

Methods

This is a prospective observational study on 48 eyes undergoing PreserFlo Microshunt implantation alone or combined with phacoemulsification. Anterior chamber depth (ACD) and volume (ACV), central corneal thickness (CCT) and total corneal astigmatism (TCA) were evaluated pre-operatively, post-operatively at day-1 and at 1 week with the Pentacam tomography. 

Results

TCA varied significantly from baseline (1.5±1.2 D) to both day 1 follow up (2.7±1.9 D, p=0.0003) and week 1 follow up (2.2±1.6 D, p=0.02). Nevertheless, mean K value didn’t show any statistical variation in the early post-operative period. CCT value rose significantly at day 1 (529±32 µm vs. 547±49 µm at baseline, p=0.04), but then returned toward pre-operative values at week 1 (537±39 µm, p=0.57). In contrast, ACD values changed insignificantly from 3.3±0.9 mm to 3.7±1.0 mm at day 1 (p=0.21), and then stabilized at 3.4±0.9 mm (p=0.82) at week 1 follow up. ACV changed from 150.0±36.2 mm3 to 159.5±42.1 mm3 at day 1 (p=0.58), and successively to 153.9±37.9 mm3 at week 1 follow up (p=0.96). The subgroup analysis in eyes undergoing standalone PreserFlo implantation didn’t show significant changes in both ACD and ACV.

Conclusion

PreserFlo implantation minimizes the anterior chamber modifications generated by traditional filtering surgery, inducing low and transient corneal and biometric changes only in the very early postoperative period and insignificant changes to ACD and ACV, label of its safety and minimal invasiveness.